Barinthus Biotherapeutics (BRNS) Other Non-Current Assets (2021 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Other Non-Current Assets came in at $914000.0 in Q1 2026, up 1.33% YoY from $902000.0 in Q1 2025, and down 1.72% on a QoQ basis from $930000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 6 years of Other Non-Current Assets data on file, last reported at $914000.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 1.33% year-over-year to $914000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $914000.0 (up 1.33% YoY) and the FY2025 annual result came in at $930000.0, up 5.56% from the prior year.
- Other Non-Current Assets retreated to $914000.0 in Q1 2026, from $930000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.1 million in Q3 2023 to a low of $138000.0 in Q3 2025.
- A 5-year average of $875882.4 and a median of $902000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets surged 30.46% — and 2025, when it tumbled 85.1%.
- Tracing BRNS's Other Non-Current Assets over 5 years: stood at $976000.0 in 2022, then declined by 9.63% to $882000.0 in 2023, then dropped by 0.11% to $881000.0 in 2024, then grew by 5.56% to $930000.0 in 2025, then fell by 1.72% to $914000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $914000.0 (Q1 2026), $930000.0 (Q4 2025), and $138000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | 919,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 919,000.00 |
| Mar 31, 2026 | 914,000.00 |
| Dec 31, 2025 | 930,000.00 |
| Sep 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 944,000.00 |
| Mar 31, 2025 | 902,000.00 |
| Dec 31, 2024 | 881,000.00 |
| Sep 30, 2024 | 926,000.00 |
| Jun 30, 2024 | 886,000.00 |
| Mar 31, 2024 | 885,000.00 |
| Dec 31, 2023 | 882,000.00 |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | 1.01 Mn |
| Mar 31, 2023 | 1.03 Mn |
| Dec 31, 2022 | 976,000.00 |
| Sep 30, 2022 | 847,000.00 |
| Jun 30, 2022 | 902,000.00 |
| Mar 31, 2022 | 788,000.00 |
| Dec 31, 2021 | 804,000.00 |
| Sep 30, 2021 | 719,000.00 |